CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
SAB-176 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04471038
NCT04471038Phase 1Completed
CompareCT.gov

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults

SAb Biotherapeutics, Inc.·interventional·Posted Jul 14, 2020·Updated Jan 6, 2025

In Brief

A Phase 1 clinical trial evaluating SAB-176 and Normal Saline for Influenza Type A and 2 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic \[Tc\] bovine-derived) intravenous therapeutic to treat past and current strains of Type A Influenza and Type B Influenza. This study will evaluate the safety, tolerability, and pharmacokinetics of SAB-176 in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza Type A, Influenza Type B, Influenza
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedJul 14, 2020
Enrollment StartJul 29, 2020
Primary CompletionApr 19, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.0 years ago

Interventions

SAB-176biological

Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)

Normal Salineother

Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm